Search results for " Humans"

showing 10 items of 2466 documents

Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic ir…

2014

Hepatitis C virus (HCV)-induced iron overload has been shown to promote liver fibrosis, steatosis, and hepatocellular carcinoma. The zonal-restricted histological distribution of pathological iron deposits has hampered the attempt to perform large-scale in vivo molecular investigations on the comorbidity between iron and HCV. Diagnostic and prognostic markers are not yet available to assess iron overload-induced liver fibrogenesis and progression in HCV infections. Here, by means of Spike-in SILAC proteomic approach, we first unveiled a specific membrane protein expression signature of HCV cell cultures in the presence of iron overload. Computational analysis of proteomic dataset highlighte…

Liver CirrhosisProteomicshepatitis C virusMaleMESH: Isotope LabelingHSCmedicine.disease_causeBiochemistry0302 clinical medicineFibrosisMESH: Up-RegulationMembrane Proteinhepatic stellate cellliver fibrosishepatic iron overload0303 health sciencesbiologyMESH: ProteomicsMedicine (all)hepatocellular carcinomaBiomedicine; hepatitis c infection; liver fibrosis; hepatic iron overload; vitronectinHepatitis C[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]Hepatitis CUp-Regulation3. Good healthcell culture-derived HCVIsotope Labeling030220 oncology & carcinogenesisHepatocellular carcinomaBiomedicine; Hepatic iron overload; Hepatitis C infection; Liver fibrosis; Vitronectin; Biomarkers; Cell Line; Hepatitis C; Humans; Iron Overload; Isotope Labeling; Liver Cirrhosis; Male; Membrane Proteins; Proteomics; Up-Regulation; Vitronectin; Molecular Biology; Biochemistry; Medicine (all)HCV[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyBiomarker (medicine)VitronectinMESH: Membrane ProteinsMESH: Liver CirrhosisHumanIron OverloadLiver CirrhosiHepatitis C virusvitronectinhepatitis c infectionCell LineMESH: Iron Overload03 medical and health sciencesmedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology030304 developmental biologyMESH: Hepatitis CMESH: HumansMESH: Biological MarkersMembrane ProteinsLiver fibrosiProteomicBiomarkermedicine.diseaseMESH: VitronectinMESH: Maledigestive system diseasesMESH: Cell LineBiomedicineBiomedicine / Abbreviations: HCCHCVccImmunologyCancer researchHepatic stellate cellbiology.proteinSteatosisBiomarkersPROTEOMICS
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensate…

2021

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaNASH; cACLD; prognostic factor; steatohepatitis[SDV]Life Sciences [q-bio]cACLD; NASH; Prognostic Factor; Steatohepatitis; Gastrointestinal Hemorrhage; Humans; Liver; Liver Cirrhosis; Retrospective Studies; Carcinoma Hepatocellular; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Liver Neoplasms; Non-alcoholic Fatty Liver Disease610 Medicine & healthEsophageal and Gastric VaricesChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInterquartile rangeInternal medicineAscitesNonalcoholic fatty liver diseasemedicineHumansComputingMilieux_MISCELLANEOUSRetrospective StudiesSteatohepatitisHepatologybusiness.industryPrognostic FactorsteatohepatitiCarcinomaLiver NeoplasmsHazard ratioGastroenterologyNASHHepatocellularcACLDmedicine.disease3. Good healthLiver030220 oncology & carcinogenesisHepatocellular carcinomaElasticity Imaging Techniques030211 gastroenterology & hepatologySteatohepatitismedicine.symptomGastrointestinal HemorrhageTransient elastographybusiness
researchProduct

Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

2014

SummaryThe burden of infectious diseases both before and after liver transplantation is clearly attributable to the dysfunction of defensive mechanisms of the host, both as a result of cirrhosis, as well as the use of immunosuppressive agents.The present document represents the recommendations of an expert panel commended by the Italian Association for the Study of the Liver (AISF), on the prevention and management of infectious complications excluding hepatitis B, D, C, and HIV in the setting of liver transplantation.Due to a decreased response to vaccinations in cirrhosis as well as within the first six months after transplantation, the best timing for immunization is likely before transp…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationInfectionsInvasive fungal infectionPostoperative ComplicationsBacterial infectionsInvasive fungal infectionsTransplantation ImmunologyLower respiratory tract infectionHumansMedicineSmallpoxVoluntary Health AgenciesIntensive care medicineImmunosuppression TherapyViral infectionsInfection ControlCirrhosiLiver transplantationAttenuated vaccineHepatologybusiness.industryVaccinationHepatitis Bmedicine.diseaseVaccinationTransplantationBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infections; Humans; Immunosuppression; Infection; Infection Control; Italy; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Transplantation Immunology; Vaccination; Voluntary Health Agencies; HepatologyCirrhosisItalyViral infectionBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infectionsAISFImmunologyBacterial infectionInfectionbusinessImmunosuppression
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct

Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Ne…

2022

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with th…

Long-acting injectable antipsychoticCross-Sectional StudiesOff-labelPersonality disorderBipolar disorderDelayed-Action PreparationsSchizophreniaHumansBipolar disorder; Long-acting injectable antipsychotics; Off-label; Personality disorder; Schizophrenia; Cross-Sectional Studies; Delayed-Action Preparations; Humans; Off-Label Use; Antipsychotic Agents; SchizophreniaOff-Label UseSettore MED/25 - PsichiatriaLong-acting injectable antipsychoticsAntipsychotic Agents
researchProduct

Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal s…

2021

Familial Mediterranean fever (FMF) is characterized by self limited episodes of fever and polyserositis.1 MEFV gene en codes for a protein named Pyrin, which plays a pivotal role in the activation and secretion of IL-1.2 Daily colchicine is highly effective in preventing attacks in this disorder in a dose-related fashion.3 Many definitions of colchicine resistance are available in the literature. The European League Against Rheumatism (EULAR) guidelines defined resistance as one or more attacks per month in compliant patients who had been receiving the maxi mally tolerated dose for at least 6 months.4 A similar definition was confirmed by a recent consensus among experts.5 In the present na…

Longitudinal studybusiness.industryFamilial Mediterranean feverInterleukinDiseaseFamilial Mediterranea fevermedicine.diseaseSymptom Flare UpColchicine; Humans; Interleukin 1 Receptor Antagonist Protein; Longitudinal Studies; Symptom Flare Up; Familial Mediterranean FeverPersistence (computer science)Familial Mediterranean Feverchemistry.chemical_compoundInterleukin 1 Receptor Antagonist ProteinSettore MED/38 - Pediatria Generale E SpecialisticachemistryColchicine Humans Interleukin 1 Receptor Antagonist Protein Longitudinal Studies Symptom Flare Up Familial Mediterranean FeverImmunologyCOLCHICINE RESISTANCEImmunology and AllergyMedicineColchicineHumansLongitudinal StudiesbusinessColchicine
researchProduct

Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis.

2021

The coronavirus disease 2019 (COVID-19) has been shown to have more severe health outcomes in older people specifically in relation to mortality and disability. Vaccination seems to be efficacious and safe for preventing the negative consequences of COVID-19, but vaccine hesitancy seems to be high in older adults. We therefore aimed to investigate the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in older people and the factors that can be associated with the unwillingness to vaccinate. For this work, we searched several databases until 18th June 2021 for studies reporting the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in pe…

Low incomeAgingCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ReviewHealth outcomesBiochemistryolder adultvaccinePrevalenceMedicineHumansMolecular Biologyolder adultsAgedbusiness.industrySARS-CoV-2VaccinationUncertaintyCOVID-19Odds ratioConfidence intervalVaccinationCross-Sectional StudiesNeurologyMeta-analysisCOVID-19; hesitancy; older adults; vaccine; Aged; Cross-Sectional Studies; Humans; Prevalence; SARS-CoV-2; Uncertainty; Vaccination; COVID-19; COVID-19 VaccineshesitancyOlder peoplebusinessBiotechnologyDemographyAgeing research reviews
researchProduct

Malnutrition in elderly: Social and economic determinants

2013

Abstract: Malnutrition occurs frequently in the frailest groups of the population, especially in people who are on a low income and elderly subjects, overall if they are institutionalized. The aim of this study was to assess the prevalence of malnutrition in a sample of elderly people living in different settings and to identify the determinants of malnutrition. Methods: A total of 718 subjects, 472 females (F) and 246 males (M), were recruited from nursing homes or were free living in three different regions in Italy. Nutritional status, depression, social, functional and cognitive status, were evaluated. Results: According to the Mini Nutritional Assessment (MNA), a high prevalence of mal…

Low incomeGerontologyMaleSettore MED/09 - Medicina InternapovertyMalnutrition elderly poverty.PopulationNutritional StatusMedicine (miscellaneous)Guidelines as TopicelderlyGeriatric populationRisk Factorspoverty; elderly; malnutrition80 and overPrevalenceElderly peopleMedicineHumanseducationGeriatric AssessmentDepression (differential diagnoses)AgedAged 80 and overeducation.field_of_studyNutrition and Dieteticsbusiness.industryMalnutritionNutritional statuselderly; Malnutrition; poverty; Aged; Aged 80 and over; Female; Geriatric Assessment; Guidelines as Topic; Humans; Italy; Male; Malnutrition; Nursing Homes; Nutrition Assessment; Nutritional Status; Prevalence; Risk Factors; Socioeconomic Factors; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and Gerontologymedicine.diseaseNursing HomesMalnutritionNutrition AssessmentItalySocioeconomic FactorsFemaleGeriatrics and GerontologybusinessNursing homes
researchProduct